This will relieve a little the tension on the delivery of doses in certain countries, in particular in France.
European Commission President Ursula von der Leyen on Wednesday announced an agreement with the BioNTech-Pfizer laboratory for the supply in March to EU countries of four million additional doses of its vaccine.
These doses will be available "before the end of the month" in addition to the deliveries already planned, and distributed in proportion to the population of the Member States, it is specified in a press release.
“This will help Member States in their efforts to control the spread of new variants” of the virus and will help “restore the free movement of goods and people,” said Ursula von der Leyen.
"Hot spots" that worry
The Commission expresses concern about several 'hot spots' in the EU for contamination, such as 'Tyrol in Austria, Nice and Moselle in France, Bolzano in Italy and parts of Bavaria and Saxony in Germany' .
Many Member States have also seen the number of infections and hospitalizations increase in recent weeks, leading some of them to impose new border controls.
In France, Ile-de-France for example exceeded the threshold of 1,000 intensive care patients on Tuesday, a first since November.
READ ALSO>
Covid-19: five minutes to understand why Europe allows itself to withhold vaccines from other countries
The Commission announced in early February that it would expect the delivery of around 55 million doses in March, an unrevised figure.
It expects a rise in vaccine deliveries in the second quarter, with 300 million doses, or 100 million per month on average, according to estimates by Ursula von der Leyen unveiled in the German press on Monday.
VIDEO.
The differences between the four main vaccines.
Three vaccines have already been approved by the EU and that of Johnson & Johnson should receive the green light from Brussels in March.
AstraZeneca has pledged to deliver 180 million doses to Europeans in the second quarter, while Pfizer-BioNTech must deliver at least 75 million according to an additional agreement signed with Brussels, in addition to unknown volumes included in the first contract.
The figures for Moderna are not known.
